Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023
Gross KL, Wedekind KJ, Kirk CA
Wegovy tablets have been studied in the OASIS clinical trial programme
Its genuinely pretty simple, and we have already written the step-by-step here: Go to their official website Take 2-min assessment quiz to get pre-approved Choose the GLP-1 treatment plan you want At this step, you will find the form you must fill out
Emergency Warning Signs Seek immediate medical attention for: Sudden vision loss in one eye (painless or otherwise) Persistent new floaters lasting more than 2 weeks Flashes of light or curtain-like vision loss New dark spots or curtain across vision Sudden changes in color vision Any abrupt, unexplained vision changes Ongoing Monitoring Schedule Non-diabetic patients: Annual comprehensive eye exams Diabetic patients without retinopathy: Annual dilated exams Diabetic patients with existing retinopathy: Quarterly exams during year 1, then as recommended Healthcare providers should also assess optic nerve anatomy